A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH

Abstract

BACKGROUND Visceral leishmaniasis (VL or kala azar) is the most serious form of human leishmaniasis, responsible for over 20,000 deaths annually, and post kala azar dermal leishmaniasis (PKDL) is a stigmatizing skin condition that often occurs in patients after successful treatment for VL. Lack of effective or appropriately targeted cell mediated immunity… (More)
DOI: 10.1371/journal.pntd.0005527

Topics

8 Figures and Tables

Cite this paper

@inproceedings{Osman2017ATG, title={A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH}, author={Mohamed Osman and Anoop Mistry and Ada Keding and Rhian Gabe and Elizabeth Ann Cook and Sarah Forrester and Rebecca C. Wiggins and Stefania Di Marco and Stefano Colloca and Loredana Siani and R. Cortese and Deborah F. Smith and Toni Aebischer and Paul M. Kaye and Charles N. J. Lacey}, booktitle={PLoS neglected tropical diseases}, year={2017} }